X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VectorY will use the proceeds to support the clinical development of VTx-002 (OPL-002), its lead vectorized antibody program targeting TDP-43 for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): OPL-002
Therapeutic Area: Neurology Product Name: VTx-002
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: MRL Ventures Fund
Deal Size: $138.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 13, 2023
Details:
Under the terms of the agreement, VectorY and Annogen will work on novel tailored cell-specific promoters to enhance VectorY’s transformative AAV-vectorized antibody platform and its potential to yield disease-modifying treatments for neurodegenerative diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Annogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 19, 2023
Details:
VecTabs, which are secreted- or intracellular-antibody fragments that are AAV-vectorized and delivered to neurons and/or astrocytes, have previously been shown to efficiently target such misfolded proteins (TDP-43) and toxic lipids (oxPL).
Lead Product(s): AAV Vector
Therapeutic Area: Genetic Disease Product Name: VecTabs
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
The new data demonstrate therapeutic potential and versatility of VectorY’s VecTab platform technology, enabling development of secreted or intracellular antibody fragments that are AAV-VecTabs delivered to neurons and/or astrocytes, in vitro and in vivo.
Lead Product(s): AAV-VecTabs
Therapeutic Area: Neurology Product Name: AAV-VecTabs
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
VTx-002, reduce TDP-43 pathological aggregates for treating ALS, TAR-DNA binding protein-43 is necessary for correct processing and transport of multiple mRNA’s that are essential for neuronal survival.
Lead Product(s): VTx-002
Therapeutic Area: Neurology Product Name: VTx-002
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
The strategy is based on the baculovirus expression system, which is already widely used for vaccine production and uses viruses that can only infect insect cells, the so-called baculoviruses.
Lead Product(s): Baculovirus-based AAV Vector
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Wageningen University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 25, 2022
Details:
Proceeds to establish pre-clinical proof of concept for vectorized antibodies in ALS and Alzheimer’s and to further expand the team.
Lead Product(s): Vectorized Antibodies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Forbion
Deal Size: $36.7 million Upfront Cash: Undisclosed
Deal Type: Financing June 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
